I often need a dumbed down version of things. This is indeed a remarkable finding!

The BULLSEYE trial found a massive, statistically significant improvement in progression-free survival (PFS) for patients treated with Pluvicto compared to those on active monitoring (deferred hormone therapy).

At a median follow-up of 27 months, the key findings for PFS were:

* Median Progression-Free Survival: Pluvicto Group: 25 months (more than 2 years of disease control).
* Control Group (Deferred ADT): 5 months.

Risk Reduction: This means the radioligand therapy reduced the risk of disease progression by a staggering 93% compared to the surveillance group. Early Progression (First 30 Weeks): During the first 30 weeks of the trial, only 7% (2 out of 29) of the patients in the treatment group experienced disease progression, compared to 93% (27 out of 29) in the control group.

It's the word "survival" that can be confusing. No one is talking about dying (that's Overall Survival). This is talking about the amount of time before you need ADT.